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There is a significant clinical need for effective therapies for primary progressive multiple sclerosis,
which presents later in life (i.e., older than 50 years) and has symptoms that increase in severity
without remission. With autologous mesenchymal stem cell therapy now in the early phases of
clinical trials for all forms ofmultiple sclerosis (MS), it is necessary to determinewhether autologous
stemcells fromolder donors have therapeutic effectiveness. In this study, the therapeutic efficacy of
human adipose-derived mesenchymal stem cells (ASCs) from older donors was directly compared
with that of cells from younger donors for disease prevention. Mice were induced with chronic
experimental autoimmune encephalomyelitis (EAE) using the myelin oligodendrocyte glycopro-
tein35–55 peptide and treated before disease onset with ASCs derived from younger (<35 years) or
older (>60 years) donors. ASCs from older donors failed to ameliorate the neurodegeneration
associated with EAE, and mice treated with older donor cells had increased central nervous system
inflammation, demyelination, and splenocyte proliferation in vitro compared with the mice receiv-
ing cells from younger donors. Therefore, the results of this study demonstrated that donor age
significantly affects the ability of human ASCs to provide neuroprotection, immunomodulation,
and/or remyelination in EAEmice. The age-related therapeutic differences corroborate recent find-
ings that biologic aging occurs in stem cells, and the differences are supported by evidence in this
study that older ASCs, compared with younger donor cells, secrete less hepatocyte growth factor
and other bioactive molecules when stimulated in vitro. These results highlight the need for evalu-
ation of autologous ASCs derived from older patients when used as therapy for MS. STEM CELLS
TRANSLATIONAL MEDICINE 2013;2:797–807
INTRODUCTION
Multiple sclerosis (MS) is a neurodegenerative
disease that is characterized by inflammation
and scar-like lesions throughout the central ner-
vous system (CNS) due to repetitive attacks by
immune cells with decreased self-tolerance for
myelin [1–3]. There is no cure for MS [4], and no
treatment ameliorates the severe forms of MS,
such as primary progressiveMS (PPMS) [5]. Thus,
there is an unmet clinical need to develop thera-
peutics to treat these patients, who often pres-
ent with debilitating symptoms without clinical
remission [1, 5]. Based on animal studies, trans-
plantation of mesenchymal stem cells (MSCs),
also called multipotent stromal cells, holds
promise as a therapy for all forms of MS [6–9].
MSCs home to areas of damage [10, 11], release
trophic factors [7, 12], and exert neuroprotective
[13–15] and immunomodulatory effects to in-
hibit T-cell proliferation [11, 15, 16]. MS-related
clinical trials have all confirmed the safety of au-
tologous MSC therapy [17–19].
It is unclear whether MSCs derived from
older MS patients, specifically PPMS patients,
have the same therapeutic potential as those de-
rived from younger patients [1, 5]. Aging is
known to have a negative impact on the regen-
erative capacity of most tissues [4, 20, 21], and
human MSCs are susceptible to biologic aging
[21–24], including changes in differentiation po-
tential, proliferation ability, and gene expression
[4, 25–27]. These age-related differencesmay af-
fect the ability of older donor cells to migrate
extensively, provide trophic support, persist
long-term, and promote endogenous repair
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mechanisms [4]. However, there are no studies in animalmodels
of neurological diseases that have compared the therapeutic po-
tential of MSCs derived from young and old donors.
To address this problem, this study used the experimental
autoimmune encephalomyelitis (EAE) mouse model of MS and
compared older (60 years) and younger (35 years) human
adipose-derivedmesenchymal stemcell (ASC) treatment effects.
Specifically, EAE-associated symptoms, motor function, spinal
cord pathology, and T-cell proliferation were assessed. A recent
study using the EAE model demonstrated that hepatocyte
growth factor (HGF) is one of the main therapeutic factors re-
leased by MSCs after transplantation [7]. Therefore, the current
study also compared the RNA levels of HGF and several bioactive
molecules of cultured young and old donor ASCs to determine
whether any age-dependent therapeutic differences are related




Female C57BL/6 mice (6–8 weeks) were obtained from Charles
River Laboratories (Willimantic, CT, http://www.criver.com);
these mice were randomly assigned to one of four mouse
groups. The established mouse colony was maintained under
standard housing conditions in the Tulane University School of
Medicine Vivarium. All animal procedures were approved by the
Institutional Animal Care and Use Committee at Tulane Univer-
sity and conformed to the requirements of the Animal Welfare
Act. Animals were housed at four or five mice per cage with free
access to food pellets andwater. In total, there were fourmouse
groups studied: 21 Hanks’ balanced saline solution (HBSS)-
treated (i.e., sham-control) EAE-induced mice (EAE), 23 EAE-in-
duced mice treated with human ASCs (hASCs) derived from
younger donors (Young), 14 EAE-induced mice treated with
hASCs derived from older donors (Old), and 17 HBSS-treated na-
ïve (i.e., no EAE induction) mice were used in this study. For
clarification purposes, the “Young” treatment group consisted of
6–8-week-oldmice that receivedASCs derived fromyoung (35
years) donors; the “Old” treatment group was a cohort of 6–8-
week-old mice that received cells from old (60 years) donors.
The animals were maintained on a 12-hour/12-hour light/dark
cycle, and video recording was consistently conducted at the
same time of day.
Induction of EAE Using the Myelin Oligodendrocyte
Glycoprotein35-55 Peptide
A myelin oligodendrocyte glycoprotein (MOG)35–55 peptide was
administered to the mice to induce chronic EAE, which models
PPMS more than other MS forms [28]. MOG35–55 peptide (Ana-
Spec, Fremont, CA, https://www.anaspec.com) was diluted (2
mg/ml) in 1 phosphate buffered saline (Invitrogen, Carlsbad,
CA, http://www.invitrogen.com) and added to equal amounts of
Complete Freund’s adjuvant (BD Biosciences, San Diego, CA,
http://www.bdbiosciences.com) with 8 mg/ml Mycobacterium
tuberculosis H35RA (catalog no. 231131; BD Biosciences). These
mixtures were thoroughly emulsified for 45 minutes using two
emulsifying syringes and a micro-emulsifying needle (Cole Par-
mer, Vernon Hills, IL, http://www.coleparmer.com). For the in-
duction of chronic EAE, the experimental animals were anesthe-
tized by 4% isoflurane in oxygen and then injected at either side
of the base of the tail with 100l of theMOG35–55 peptide emul-
sion (200 l total per mouse) via a subcutaneous route. While
under anesthesia, the mice were also injected with 200 ng of
pertussis toxin (2 ng/l; List Biologicals Laboratories, Campbell,
CA, http://www.listlabs.com) through intraperitoneal (i.p.) ad-
ministration. Each animal also received i.p. administration of 100
l of HBSS, young hASCs (1  106 cells), or old hASCs (1  106
cells). This EAE induction day was designated as 0 days postim-
munization (0 DPI). After 48 hours, the mice received an addi-
tional 100l of 200ngof pertussis toxin (2 ng/l) through the i.p.
route. All solutions were injected with a 1-ml syringe with a 27-
gauge 3/8-inch needle.
Collection, Culture, and Injection of Human ASCs
The hASCs were obtained from six female patients who were
classified as younger (n 3;35 years old) or older (n 3;60
years) donors. All cells were isolated from processed lipoaspi-
rates, characterized, and cultured as previously described [27].
The young donor ASCs had amean SD age of 26.3 3.8 years,
and the old donor ASCs had a mean SD age of 63 1.4 years.
In addition to donor age, the race and selected demographics
were obtained and analyzed; there were no other significant
demographic differences, including body mass index. All cells
were isolated after review and approval by the institutional re-
view board of Tulane University School of Medicine, Pennington
Biomedical Research Center, or Brigham andWomen’s Hospital/
Harvard Medical School with informed patient consent.
Passage two (P2) hASCs were recovered from cryopreserva-
tion in -minimum essential medium (-MEM; Invitrogen) with
20% fetal bovine serum (FBS; Atlanta Biologicals, Lawrenceville,
GA, http://www.atlantabio.com), 1% L-glutamine (Invitrogen),
and 1% penicillin-streptomycin (pen-strep; Invitrogen). All cells
were grown separately for each individual donor, and the me-
diumwas changed on the second day followed by every 2–3 days
thereafter until the cells reached 70% confluence. The cells were
washed thoroughly with 1 phosphate-buffered saline (PBS; In-
vitrogen), incubated at 37°C with trypsin for 3 minutes (Invitro-
gen), neutralized with an equal volume of complete media, and
counted using a Countess Automated Cell Counter (Invitrogen).
For expansion purposes, the cells were then replated at 250 cells
per cm2. The media were changed every 2–3 days, and the cells
were again lifted with trypsin once they reached 70% conflu-
ence. The viabilities of the lifted cells were consistently greater
than 90% (data not shown), and all donor cell populations were
grown and lifted on the same days. Additionally, these cells were
analyzed using flow cytometry, and no differences were found in
the size of the cells using side and forward light-scattermeasure-
ments [27]. For harvesting, the lifted and neutralized cells were
centrifuged at 420g for 7 minutes at room temperature, and the
cell pellet was resuspended with HBSS (Fisher Scientific, Pitts-
burgh, PA, http://www.thermofisher.com) containing calcium
and magnesium but no phenol red. At this point the younger
donor cells were pooled together and the older donor cells were
pooled together for injection purposes. The two cell populations
(i.e., younger andolder cells)were kept off ice for 30minutes and
then returned to ice for no longer than 1 hour prior to injection.
Before injection, the cell suspension was mixed thoroughly by
inversion and warmed to room temperature. All treated animals
received injections of 100 l of the appropriate cell suspension
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(1 106 total younger or older ASCs) or HBSS into the left side of
the peritoneal cavity at 0 DPI, as described above.
Clinical Scoring of EAE Mice
Beginning at 0 DPI, clinical scoring was performed daily to mon-
itor the severity of the EAE-associated symptoms and averaged
from three independent observers, who were blinded to the
treatment groups. These observations were performed three
times each day between 8:00 a.m. and 5:00 p.m. (i.e., when the
micewere awake). Tail and hind limb paralysis were scored using
the following scoring system: 0, complete absence; 1, tail atony
(i.e., loss of tail tone); 2, hind limb weakness with no apparent
paralysis; 3, partial hind limb paralysis affecting only one leg; 4,
complete paralysis with no leg movement; and 5, death. Any
death was recorded as a score of 5 for the day of death and any
subsequent day for the remainder of the study.
Video Tracking for Motor Function Assessment
Video recording of eachmousewas conducted at 3, 7, and 14DPI
using a LifeCam Cinema webcam with True 720p HD video and
Debut Video Capture Software (Microsoft, Redmond, WA,
http://www.microsoft.com) as describedpreviously [29]. Briefly,
all video files were uploaded for analysis using the EthoVision
XT7 software (Noldus IT, Wageningen, The Netherlands, http://
www.noldus.com) for quantification of various spatial end-
points, such as mean velocity, total distance traveled, and mov-
ing duration [30, 31]. EthoVision XT7 generated JPEG images of
each mouse’s tracks after the 5-minute recording period, and
these tracks were compared per mouse group to visualize differ-
ences in activity within the arena. A blinded analyst assessed the
track densities both visually and using Fiji/ImageJ software (Na-
tional Institutes of Health, Bethesda, MD) as previously de-
scribed [29, 32].
Tissue Processing and Histological Staining
Animals were killed by exposure to CO2, and spinal cords were
removed and stored at room temperature in 10% neutral buff-
ered formalin. Paraffin-embedded sections were cut at 5 m,
mounted on glass slides, and subsequently stained with Luxol
fast blue (LFB) and hematoxylin and eosin (H&E) for identifica-
tion of intact myelin and infiltrating cells, respectively. Slides
were scanned using an Aperio ScanScope CS instrument (Aperio
Technologies, Inc., Vista, CA, http://www.aperio.com), and the
LFB imageswere analyzedwith Aperio software (Aperio Technol-
ogies) to quantify the intensity of the blue staining per section as
a percentage of blue pixels per total pixels. For each mouse
group, LFB stains of four mice (three sections per mouse) were
analyzed. The H&E images were analyzed with Fiji/ImageJ soft-
ware to quantify the number of total cells (i.e., cells5m2) per
field at400magnification [32]. For each treatment group, H&E
stains of three mice (two sections per mouse) were analyzed.
The total number of cells per field for each representative H&E
image corresponds to the average number of cells per field for
the respective mouse group. The investigators who performed
the tissue investigations were blinded to the mouse groups
until the end of the experiment after graphswere generated and
tissue sections were compared.
Protein Isolation
The spinal cords and spleens were collected and stored at 4°C in
Allprotect tissue reagent solution (Qiagen, Hilden, Germany,
http://www.qiagen.com). For protein isolation, each samplewas
homogenized in 0.2% Nonidet P40 in PBS using a plastic motor-
ized pestle; approximately 10 ml of fluid was used per gram of
sample. All samples were exposed to 10 rounds of sonication,
with each round consisting of 5 seconds of sonication and 20
seconds on ice without sonication. The solutions were centri-
fuged twice for 5 minutes at 12,000g, and the supernatant was
removed and saved in aliquots at 20°C for future enzyme-
linked immunosorbent assay (ELISA) analyses. Protein concen-
trationwas determined using the BCA assay (Pierce, Rockford, IL,
http://www.piercenet.com), and all protein lysates were centri-
fuged using Ultrafree-MC centrifugal filter units with micropo-
rousmembranes (Millipore, Billerica,MA, http://www.millipore.
com) before testing.
Cytokine/Chemokine ELISA
At 15 DPI, the sera of fivemice per treatment groupwere pooled
together and stored at80°C prior to testing. A total of 25 l of
neat serum sample (n 5 mice per sample) was loaded in dupli-
cate onto four 96-well ELISA plates (Invitrogen) at room temper-
ature. These precoated plates were used to detect interleukin
(IL)-12, IL-17, interferon- (IFN-), or tumor necrosis factor-
(TNF-). Specific polyclonal antibodieswere added afterwashing
followed by the addition of a substrate solution; all steps were
performed according to the manufacturer’s instructions. For
each plate, the absorbance values were measured at 450 nm on
a fluorescent microplate reader (FLUOstar Optima; BMG
Labtech, Ortenberg, Germany, http://www.bmglabtech.com),
and the values of cytokine levels were calculated based on the
standard curve.
T-Cell Proliferation Assay
Immediately after euthanasia, four spleens per mouse group
were briefly stored on ice in -MEM (1 hour), homogenized
gently using the blunt end of a sterile 10-ml plastic syringe, fil-
tered through a 70-m cell strainer (BD Biosciences), and
washed twice with 1 PBS. The filtrate was centrifuged at 1,200
rpm for 10 minutes, resuspended in 2 ml ammonium-chloride-
potassium (ACK) red blood cell lysis buffer (Invitrogen) for 3min-
utes, centrifuged again at 1,200 rpm for 7 minutes, and then
resuspended in RPMI 1640 (Sigma-Aldrich) with 2 mM L-glut, 2
mM pen-strep, 10% FBS, and 50 M -mercaptoethanol. The
splenocytes were counted using a Countess Automated Cell
Counter (Invitrogen). For each 96-well plate, splenocytes of four
mice per treatment group were plated in triplicate at 2  105
cells per well in 200 l of complete RPMI 1640. For the PBS
condition, the splenocytes were grown for 48 hours in complete
RPMI 1640 with the addition of 10 l of PBS. For the MOG con-
dition, a 96-well plate was incubated with MOG35–55 peptide at
30g/ml and then blotted dry, leaving the plate coated with the
peptide; the splenocyteswere then added to theprecoatedplate
and grown for 48 hours in complete RPMI 1640. For the stimu-
lated condition, the splenocyteswere grown for 48 hours in com-
plete RPMI 1640with the addition of 1g/ml anti-CD3monoclo-
nal antibody (mAb) and 2 g per well of anti-CD28 mAb
(BioLegend, San Diego, CA, http://www.biolegend.com).
A 5-bromo-2-deoxyuridine (BrdU) cell proliferation assay
(Cell Signaling Technology, Beverly, MA, http://www.cellsignal.
com)was used to determine the cell proliferation activity of each
well. Briefly, 20l perwell of 10 BrdU solutionwas added after
the cells had grown for 48 hours. After 18 hours of incubation
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with BrdU, the plates were centrifuged at 300g for 10 minutes;
the media were removed; and a fixation/denaturing solution, an
anti-BrdU antibody, and a horseradish peroxidase-conjugated
secondary antibodywere added according to themanufacturer’s
instructions. To quantify the amount of BrdU that was incorpo-
rated by the proliferating cells, a TMB (tetramethylbenzidine)
substrate was incubated for 30minutes, and samples weremea-
sured at 450 nm on a fluorescent microplate reader (FLUOstar
Optima) following the addition of the provided STOP solution.
ASC Stimulation, RNA Isolation, and Reverse
Transcription-Polymerase Chain Reaction
P2 hASCs derived from younger or older donors were grown to
70% confluence in complete -MEM, lifted as previously de-
scribed with trypsin, and then seeded into six-well plates at a
density of 2 105 ASCs per well. After 24 hours, themedia were
removed and replaced with either fresh, complete -MEM or
macrophage-conditioned medium that had been taken directly
from confluent primary RAW 264.7 (catalog no. TIB-71; Ameri-
can Type Culture Collection, Manassas, VA, http://www.atcc.
org) mouse macrophage cells grown in Dulbecco’s modified Ea-
gle’s medium (American Type Culture Collection) with 10% FBS
(Atlanta Biologicals) and 1% pen-strep (Invitrogen). Thus, there
were four cell populations in all (e.g., Young, Young-Stimulated,
Old, and Old-Stimulated). For RNA isolation, the cell pellets were
obtained and homogenized using a QIAshredder (Qiagen) ac-
cording to the manufacturer’s instructions. The isolation was
completed on ice using the RNeasy Qiagen protocol without
modifications to the cell RNA isolation protocol. DNase 1 Am-
plification Grade (Invitrogen) was added to 1 g of RNA for 15
minutes at room temperature, and 1 l of EDTA (25 M) was
added at 65°C for 10 minutes to stop this reaction. DNase-
treated RNAwas then converted to complementary DNA (cDNA)
using the iScript protocol and reagents (Bio-Rad, Hercules, CA,
http://www.bio-rad.com). The cDNA were then tested for the
presence of various cytokines/chemokines and growth factors
(e.g., HGF, IL-1, IL-2, IL-8, IL-10, IL-12) and glyceraldehyde-3-
phosphate dehydrogenase using real-time reverse transcription-
polymerase chain reaction (PCR). All primer sequences were re-
ported in a previous study [12]. All RNA and cDNA aliquots were
quantified for RNA or DNA content using a NanoDrop Spectro-
photometer 2000 (Thermo Scientific, Waltham, MA, http://
www.thermoscientific.com).
Statistical Analysis
For comparisons of clinical scores, two-way analysis of variance
(ANOVA) was performed using GraphPad Prism 4.0b for Macin-
tosh at 10–14 and 26–30 DPI, and all values were reported as
mean SEM. For tests with a significant (p .05) time group
interaction, pairwise comparisons of least square means were
made to further investigate the interaction. For the behavioral,
neurophenotyping, andhistological studies, statistical analysis of
three or more groups was performed using one-way ANOVA fol-
lowed by pairwise comparisons of the mouse groups using Bon-
ferroni post hoc testing. Significance for the overall group effect
and individual pairwise comparisons was defined as p  .05. A
two-tailed Student’s t test was performed to evaluate differ-
ences in RNA levels of various factors for the old and young
hASCs. Disease incidence ratios (i.e., number of animals with EAE
symptoms per number of animals injectedwithMOG)were com-
pared using a contingency table and a 2 test.
RESULTS
Assessment of EAE Symptoms Using Observational and
Automated Phenotyping Methods
All mice were weighed on DPI 0 before EAE induction, and there
were no significant weight differences between the four mouse
groups (p .71). The EAE-inducedmiceweremonitored daily for
scoring of tail and hind limb paralysis, revealing a significant
group time interaction (p .0001), group effect (p .0001),
and time effect (p .0001) over the course of the study (Fig. 1A).
Bonferroni post hoc testing was performed at 10–14 and 26–30
DPI for comparisons between the three mouse groups. None of
the naïvemice presentedwith tail or hind limb paralysis over the
duration of the study. The Young treatment group, which re-
ceived hASCs from younger donors, had significantly improved
scores compared with the sham-control EAE mice at 10–14 DPI
(p  .01 to .001). However, at 26–30 DPI, the Young mice had
Figure 1. Young, but not old, donor adipose-derivedmesenchymal stemcells improve EAE clinical presentation. (A): The clinical scores for the
EAE (n  21), Young (n  23), and Old (n  14) mouse groups were recorded daily for the duration of the study. The Young group had
significantly lower scores and less paralysis compared with the EAE group for all time points tested (p .01 to .001) and the Old group for
26–30 DPI (p  .001). All non-EAE control mice (Hanks’ balanced saline solution, naïve) had scores of 0 for every time point and are not
included in the group comparisons. All values represent means SEM. Significance was defined as follows: , p .05; , p .01; , p
.001 versus EAEmice; ###, p .001 versus Oldmice. (B): The number ofmicewith each clinical score (0–5) is shown for each treatment group
at 14 DPI. The majority of young mice had clinical scores of 0 (i.e., no disease), whereas the majority of Old and EAE groups presented with
EAE-associated symptoms corresponding to scores of 1 and 3, respectively. Abbreviations: DPI, days postimmunization; EAE, experimental
autoimmune encephalomyelitis; hASC, human adipose-derived mesenchymal stem cell.
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significantly lower clinical scores, and thus less paralysis, than
both the sham-control EAE and Old groups (p .001). ASCs de-
rived fromolder donors hadnoeffect on the clinical presentation
of the EAE-inducedmice, as therewere no significant differences
in clinical score between the sham-control EAE and Old mouse
groups at any time point in this study (Fig. 1A). To evaluate the
distribution of clinical scores per treatment group, the number of
animals with each clinical score at 14 DPI was recorded. As
shown in Figure 1B, the Young mice (n  23) had a mode of 0,
with 10mice showing no evidence of disease. In contrast, theOld
(n 14) and EAE (n 21) groups had modes of 1 and 3, respec-
tively (Fig. 1B). All EAE-induced mouse groups, regardless of
treatment, demonstrated the characteristic chronic disease pro-
gression of EAE with presentation of symptoms between 7 and
10 DPI, peaking of symptoms by 15 DPI, and maintenance of
disease severity after 15 DPI. However, the younger hASCs were
able to alleviate EAE-associated symptoms, whereas the cells
from older donors failed to improve the severity of the disease.
Neither the younger nor the older hASCs significantly de-
layed the onset of the EAE symptoms, which started at 8.89 
0.85, 9.67  0.84, and 10.47  0.89 DPI for the EAE, Old, and
Young mouse groups, respectively (Table 1). The disease inci-
dences for the EAE, Old, and Young mouse groups were 19 of 21
(90.5%), 12 of 14 (85.7%), and 17 of 23 (73.9%), respectively, and
there were no significant difference between the cell treatment
groups and the sham-controls (Table 1). There was a significant
Figure 2. Young adipose-derived mesenchymal stem cell-treated mice have increased activity and motor function. (A): Track visualizations
were generated using EthoVision XT7 for the naïve HBSS (n 6), Young (n 6), Old (n 6), and EAE (n 6)mouse groups at 3, 7, and 14 days
postimmunization (DPI). For any given day, a mouse was recorded once for 5 minutes, and representative images are shown. The tracks for
the EAE and Old mice showed a marked decrease in track density, especially in the inner zone of the arena, seen as early as 7 DPI. The Young
and naïve HBSS mice demonstrated increased activity per recording period compared with the EAE and Old mouse groups. (B): The total
distance traveled in 5minutes was compared across all mouse groups at 7 DPI. (C): The average velocity over 5minutes was compared across
all mouse groups at 7 DPI. (D): The time spent in motion over 5 minutes was compared for all mouse groups at DPI 7. Comparisons between
mouse groups were made using one-way analysis of variance and Bonferroni’s post hoc testing. , p .05 versus naïve HBSS mice; #, p .05
versus EAE mice. Abbreviations: EAE, experimental autoimmune encephalomyelitis; hASC, human adipose-derived mesenchymal stem cell;
HBSS, Hanks’ balanced saline solution.








Total cells (>5 m)




EAE (21 mice) 8.90  0.85 (8.0) 19/21 (90.5%) 2.29  0.20 (2) 1054  83 49.77  0.90
Young hASCs (23 mice) 10.47  0.89 (10) 17/23 (73.9%) 1.58  0.18a (1) 828  47a 58.97  1.72a
Old hASCs (14 mice) 9.67  0.84 (9.5) 12/14 (85.7%) 2.25  0.36 (2) 1231  48 48.61  1.38
ap .05 vs. Old mice.
Abbreviations: DPI, days postimmunization; EAE, experimental autoimmune encephalomyelitis; H&E, hematoxylin and eosin; hASC, human
adipose-derived mesenchymal stem cell; LFB, Luxol fast blue.
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group effect on themaximum clinical score achieved (F [2, 56]
4.10; p  .022), and post hoc testing demonstrated that the
Young group had less severe maximum scores than the EAE
mouse group (p .05; Table 1).
As shown by the representative track visualizations (Fig. 2A),
the EAE andOldmice showedamarkeddecrease in activity in the
arena at 7 and 14 DPI. In contrast, the naïve and Young mice
showed increased activity andutilization of the arena space com-
pared with the EAE and Old mice. Analysis of automated and
observational behaviors further demonstrated significant differ-
ences between themouse groups, with a significant group effect
on total distance traveled (F[3, 24]  4.79; p  .009), average
velocity (F(3, 24)]  4.96; p  .026), and moving duration (F[3,
24]  5.43; p  .021) during the 5-minute recording period on
DPI 7 (Fig. 2B–2D). Compared with the naïve mice, the EAE mice
had a significant decrease in total distance traveled, moving ve-
locity, and time spent moving (p .05), whereas the Young and
Old groups did not differ from the naïve mice. The younger, but
not older, hASC-treated mice showed improved distance trav-
eled and velocity compared with EAE mice (p .05; Fig. 2C).
Histological Analysis of the Spinal Cord
As a prototype for inflammatory neurodegenerative diseases,
the EAE mouse has increased inflammation throughout the CNS
with lesions that resemble the pathology in the human patient
[17, 28, 33]. To determine the effects of hASC treatment on my-
elin levels in the EAEmice, spinal cordswere obtained at sacrifice
and analyzed for intact myelin after LFB staining. The LFB images
(Fig. 3A) showed areas of demyelination that contained low in-
tensity LFB staining throughout the spinal cord sections for both
the EAE and Oldmouse groups. The Youngmice had significantly
more intactmyelin than bothOldmice and EAEmice (Fig. 3C, p
.001). However, the older hASC treatment had no significant ef-
fect on myelin levels compared with the EAE mice. Compared
with the naïve mice, the spinal cords from the Young mice had
similar myelin levels and the Old and EAE spinal cords had signif-
icantly less intact myelin (Fig. 3C, p  .001). H&E staining was
performed to evaluate the levels of infiltrating cells in the spinal
cords of all treatment groups. The younger hASC treatment sig-
nificantly decreased the number of infiltrating cells present in
the spinal cords compared with the EAE control and the older
hASC-treated mice (Fig. 3B, p .001).
Effects of Cell Therapy on Splenocyte Proliferation
Splenocytes isolated from the four mouse groups at sacrifice
were grown in the presence of 1 PBS, MOG35–55, or anti-CD3
mAband then tested for cell proliferation using a BrdUassay (Fig.
4). Comparing the cells grown with PBS only, the cells isolated
from the naïve and Young mouse groups proliferated less than
the cells of the Old group (p  .01). The cells isolated from the
naïve and Young mice proliferated less than the EAE mouse cells
when grown in thepresenceofMOG35–55 peptide (p .05), even
Figure 3. Cell therapy effects on myelin and infiltrating cell levels in the spinal cord of EAE-induced mice. (A): Spinal cords were obtained at
sacrifice from four mice per mouse group (naïve HBSS, Young, Old, and EAE). Each spinal cord was sectioned, mounted, and stained with LFB
or H&E for comparison of intact myelin levels and infiltrating cells, respectively. Images were acquired at magnifications of40 and1,000
for the LFB-stained sections and400 for the H&E sections. (B): The H&E-stained sections (n 3mice; 2 sections permouse) were quantified
for the number of total cells per field at 400 magnification using ImageJ/Fiji software. (C): The LFB-stained sections (n  4 mice; three
sections per mouse) were quantified for the intensity of the blue staining using Aperio software. Comparisons between mouse groups were
made using one-way analysis of variance and Bonferroni’s post hoc testing. , p .001 versus naïve mice; ###, p .001 versus Old mice.
Abbreviations: EAE, experimental autoimmune encephalomyelitis; H&E, hematoxylin and eosin; HBSS, Hanks’ balanced saline solution; LFB,
Luxol fast blue.
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though there was no difference in proliferation between the Old
and EAE cells after exposure toMOG35–55. All cells had increased
proliferation when exposed to antibodies targeting CD3 and
CD28; however, even in this stimulatory environment, the cells
from the naïvemice had less proliferative capacities than theOld
mouse splenocytes (p .05).
Analysis of Proinflammatory Cytokines in the Serum
The sera of five mice per mouse group were obtained at 15 DPI,
pooled together, and analyzed for levels of different proinflam-
matory cytokines using ELISAs (Fig. 5). The EAE-induced mice,
regardless of treatment, had greater levels of IL-12, IL-17, IFN-,
and TNF- in their sera than the naïve mice. Serum levels of
TNF- were consistent across the Young, Old, and EAE groups.
The serum levels of IFN- were increased in the Old group and
further increased in the Young group, compared with the EAE
controls. In contrast, IL-17 levels were increased in the Young
group and further increased in the Old group compared with the
EAEmice. Also, the Youngmice had greater serum levels of IL-12
than any other group, including the Old group.
Analysis of Cytokines and Growth Factors in hASCs
Derived From Young and Old Donors
The RNA levels for different cytokine or growth factors in hASCs
derived from younger and older donors were determined using
real-time PCR (Fig. 6). Without stimulation, there were no signif-
icant differences between the younger and older hASCs for any
factor. The younger and older cells were then exposed to mac-
rophage-conditioned media, and the younger hASCs expressed
significantly more HGF and IL-1 RNA, with slightly increased
RNA levels of IL-2, IL-8, IL-10, and IL-12. Because of recent find-
ings that HGF is a therapeutic factor released byMSCs in the EAE
MS model [7], we investigated the role of HGF, specifically in
regard to any pathways that may be dysregulated with age in
MSCs. Analysis of younger and older hASCs using Ingenuity Path-
way Analysis (IPA) and the Ingenuity Knowledge Base demon-
strated an altered HGF-related signaling pathway (data not
shown); specifically, extracellular signal-regulated kinase 1/2
(ERK1/2) and mitogen-activated protein kinase (MAPK) are
markedly downregulated in older human ASCs, as previously re-
ported by our laboratory using IPA, mRNA, and protein analyses
[27]. The differentiation potential, proliferation ability, andmor-
phology of the young and old ASCs were reported in the same
study from our laboratory [27].
DISCUSSION
Older donor MSCs of various species have decreased differenti-
ation potential and proliferative capability [12, 20, 22, 26] and
altered gene expression [12, 22, 34] compared with younger do-
nor MSCs. Furthermore, demonstrated differences in signaling
pathways [27, 35], methylation patterns [36], oxidative stress
levels [35, 37], microRNA expression [20, 27], telomere length
[23, 24], and growth factor production [12, 34] suggest that
MSCs derived from older donors may have decreased therapeu-
tic effectiveness after transplantation. To test this possibility, our
study is the first to compare the age-related therapeutic effects
of human ASCs derived from older and younger donors using the
EAE mouse model of MS.
To ensure that this study was clinically relevant to the popu-
lation in question (i.e., late-onset PPMS patients), EAE was in-
duced using theMOG35–55 peptide in order to simulate a chronic
disease state. The improved clinical scores andmotor function of
the EAE-induced mice receiving younger donor ASCs indicate
that younger, but not older, ASCs are capable of halting EAE
disease progression before the development of hind limb paral-
ysis. Although the stem cells from older donors do not seem to
exacerbate EAE in the mouse, our results indicate that older do-
nor MSCs have lost the ability to alleviate EAE-associated symp-
toms. The striking differences in clinical presentation between
younger and older hASC-treated EAE mice emphasize the need
to determine the therapeutic effectiveness of autologous cell
transplantation in older patients, especially those with demyeli-
nating or inflammatory diseases like MS.
To understand why the older ASCs had no therapeutic effect
in the EAE model, we evaluated the effect of donor age on the
MSCs’ ability to improve EAE CNS pathology, decrease T-cell pro-
liferation, and produce relevant therapeutic factors. Spinal cords
of all mouse groups were evaluated for differences in intact my-
elin levels using LFB staining. The increased blue intensity asso-
ciated with the younger ASC-treated mouse group and the ex-
tensive demyelination present in the older ASC-treated mice
indicated that the younger donor cells were capable of providing
neuroprotection through inhibition of demyelination or promo-
tion of remyelination. Supporting this result, a recent study dem-
onstrated that ASCs can stimulate endogenous progenitors, such
as oligodendrocyte progenitors, to differentiate into their adult
myelin-producing counterparts [4]. We also found that donor
age has an effect on the ability of the MSCs to decrease inflam-
matory infiltration in the spinal cord. Collectively, our results
suggest that older ASCs are less therapeutic for EAE mice be-
cause of their inability to decrease demyelination and inflamma-
tion in the spinal cord.
Figure 4. 5-Bromo-2-deoxyuridine (BrdU) cell proliferation assay
with mouse splenocytes. Mouse spleens were isolated from the na-
ïve HBSS (n 4), Young (n 4), Old (n 4), and EAE (n 4) mice at
sacrifice, and splenocytes were cultured in the presence of PBS
(blue), MOG35–55 (30 mg/ml; red), or CD3 and CD28 antibodies
(green). A BrdU cell proliferation assay was used to compare the
proliferation abilities of the four splenocyte populations in the three
growth conditions. The splenocytes of the Old group had greater
proliferation at baseline (i.e., with only PBS added) compared with
the naïve and Young mice (p  .01); similarly, the Old group had
increased proliferation compared with naïve HBSS mice after stimu-
lation with CD3 and CD28 antibodies (p  .05). The EAE mice had
greater proliferation afterMOG35–55 exposure when compared with
the naïve HBSS and Young groups (p  .05). Comparisons between
mouse groups were made using one-way analysis of variance and
Bonferroni’s post hoc testing. , p .05 versus EAEmice; #, p .05;
##, p .01 versus Old mice. Abbreviations: EAE, experimental auto-
immune encephalomyelitis; HBSS, Hanks’ balanced saline solution;
MOG, myelin oligodendrocyte glycoprotein35–55; PBS, phosphate-
buffered saline.
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The increased inflammation in the spinal cords of the older
ASC-treated mouse cohort led us to evaluate the immunomodu-
latory effects of young and old human MSCs. The T-cell prolifer-
ation in vitro assay is commonly used to determine whether the
T cells residing in an animal’s spleen are primed for proliferation
because of their previous exposure to the MOG35–55 peptide in
vivo. Thus, any treatment that inhibits T-cell proliferation in vivo
should also result in decreased in vitro T-cell proliferation even
when cultured in the presence of MOG35–55. In contrast, un-
treated animals should have increased T-cell proliferation after
being cultured with MOG35–55 because of their previous expo-
sure to the peptide in vivo. All T cells, regardless of mouse or
treatment group, should proliferate in the presence of the CD3
and CD28 antibodies because of the direct stimulatory effect. In
the current study, the T-cell proliferation assay results indicate
that older MSCs may actually stimulate, and not inhibit, the pro-
liferation of the T cells. In contrast, the results suggest that
younger ASCs are capable of inhibiting the proliferation of T cells
compared with the EAE cells in the presence of MOG35–55. A
decrease in T-cell proliferation would result in a decreased num-
ber of T cells available to attack the CNS in the mice, which di-
rectly supports the histological results that the CNS damage and
inflammation are less severe in the young ASC-treatedmice than
in the old ASC-treated mice.
Although the histopathological findings in the spinal cord
and the T-cell proliferation assay demonstrated therapeutic ef-
fects in the affected mouse group receiving young hASCs, the
serum proinflammatory cytokine levels at the peak of disease
(DPI 15) were elevated compared with the naïve mice and not
improved compared with the shammice or mice receiving older
hASCs. These ELISA results indicate that young hASCs are not
capable of alleviating the systemic inflammation associated with
EAE; these findings may explain why several mice receiving
young cells became partially or completely paralyzed. Injected
ASCs must be distributed in high enough numbers to perform
systemic and local anti-inflammatory actions; thus, it is likely that
a higher dose of ASCs should be initially used or an additional
injection of ASCs should beprovided (e.g., second injection atDPI
10) to increase the number of ASCs available to provide thera-
peutic benefit in the EAE-affected mice.
A recent article has demonstrated that HGF is a main thera-
peutic factor released by bone marrow-derived MSCs (BMSCs)
when transplanted in EAEmice [7]. Bai et al. provided compelling
evidence that both BMSCs and BMSC-conditioned media lose
their therapeutic effectiveness when combined with anti-HGF
antibodies [7]. Recent studies have also shown that HGF gene
expression decreases with donor age in BMSCs and ASCs [12, 20,
34]. Collectively, these independent studies indicate that ASCs
from older donors may have decreased levels of the main ther-
apeutic agent necessary to provideCNSprotection in EAEmice or
MS patients. To test this hypothesis, the RNA levels of HGF and
various cytokines were compared after culturing the old and
young ASCs with and without stimulation.
Our data indicate that the younger cells have increased gene
expression of HGF after stimulation compared with the older
stem cells. HGF is a cytokine that promotes angiogenesis and cell
survival [7], and it is also involved in the activation of ERK1/2 and
MAPK pathways [38]. Directly supporting this finding, a previous
study in our laboratory demonstrated that older donors have
decreased expression of ERK1/2 andMAPK/p38 [27]. Therefore,
Figure 5. Mouse serum protein levels of proinflammatory cytokines. Sera were pooled from five mice per mouse group at 15 days postim-
munization and tested on four enzyme-linked immunosorbent assay plates to detect levels of IL-12, IL-17, IFN-, and TNF-. The protein
concentrations for all four cytokines were elevated for the EAE-induced mice compared with the HBSS controls. The Old mice had increased
IL-17 levels compared with all groups, and the Young mice had increased IL-12 and IFN- compared with all groups. Abbreviations: EAE,
experimental autoimmune encephalomyelitis; HBSS, Hanks’ balanced saline solution; IFN, interferon; IL, interleukin; TNF, tumor necrosis
factor.
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the age-associated decline of HGF expression and disruption of
signaling pathways in human ASCs may directly relate to the
decreased therapeutic potential of ASCs from older donors. To
further test this hypothesis, ongoing experiments in our labora-
tory have been designed:MSCs derived fromolder donorswill be
genetically modified to overexpress HGF or supplemented with
recombinant HGF upon transplantation to achieve improved
therapeutic efficacy, and HGF antibodies will be used in conjunc-
tion with in vivo experiments to test whether there is a loss of
activity of the young cells. However, any protocols designed to
increase HGF levels must also take into consideration the route
of administration because of HGF’s potent mitogenic effect on
hepatocytes [7].
The age-related decrease of cytokines, specifically IL-1,
has been documented in several studies using human BMSCs
and ASCs [20, 27]. Because MS involves chronic activation of
microglia and macrophages [1, 3], it is appropriate to assume
that the younger ASCs in this study provide better clinical
benefit because of their ability to release of trophic factors
after their activation in inflammatory disease states. Such ef-
fects are probably attributable to the age-related increases in
nuclear factor-B [20, 27] and DNA damage [35] and de-
creases in cell cycle regulators (e.g., p53, p21) [34], growth
factors (e.g., HGF, vascular endothelial growth factor) [20,
34], and genomic stability (i.e., telomere length) [21]. A pre-
vious study from our laboratory highlighted significant age-
related differences in the expression of microRNAs in human
BMSCs and ASCs [27]. Our previous study demonstrated using
histochemical staining of differentiation assays that ASCs
have significantly less mineralization and lipid production in
older donors than do those in younger donors (p .05), dem-
onstrating that the differentiation capabilities of ASCs are po-
tentially linked to biological age of the donor [27]. Although it
is unlikely that the therapeutic effects of the injected ASCs in
the EAE mouse model are due to their in vivo differentiation,
it is likely that other properties (e.g., migration ability and/or
overall viability) could be similarly affected by biologic aging.
The stem cells of older donors have increased apoptosis [22],
altered methylation patterns [36], altered secretomes (e.g., de-
creased IL-1) [27, 37], and excessive activation of Wnt/b-
catenin signaling [35]. A recent study compared young (1–3
months) and aged (18–24 months) mouse ASCs in normoxic
Figure 6. Young human adipose-derived mesenchymal stem cell (hASCs) have increased RNA levels of various cytokine and growth factors
compared with old hASCs. hASCs derived from young or old donors were grown with and without stimulation by macrophage-conditioned
media. The hASCs derived from young donors had increased levels of RNA for HGF and IL-1 after stimulation and slight increases for IL-2, IL-8,
IL-10, and IL-12 when left nonstimulated. Comparisons between mouse groups were made using one-way analysis of variance and Bonfer-
roni’s post hoc testing. , p .05; , p .01 versus Old mice. Abbreviations: HGF, hepatocyte growth factor; IL, interleukin.
805Scruggs, Semon, Zhang et al.
www.StemCellsTM.com ©AlphaMed Press 2013
(20%) and hypoxic (1%) conditions, and it was found that aged
ASCs in hypoxic conditions have decreased proliferation poten-
tial and telomere lengths, increased frequency of apoptosis, and
changed angiogenic properties [39]. Therefore, it is also possible
that older human stem cells are also more sensitive to toxic en-
vironments, such as in vivo hypoxia after transplantation, and
may have impaired therapeutic potential because of decreased
proliferation or increased apoptosis.
This proof-of-concept study demonstrates that ASCs de-
rived from older donors have a decreased therapeutic effec-
tiveness compared with young donor cells when injected into
an MS mouse model. It is likely that biologic aging of the
human stem cells led to the differences in clinical and/or his-
topathological outcomes, and we predict that older donor
MSCs would also lack therapeutic effectiveness in the human
MS patient. Although a similar study has yet to be performed
in a human population, several clinical trials have imple-
mented autologous humanMSC treatment for progressiveMS
patients. Thus far, all MS clinical trials that have included pa-
tients of young and old ages have demonstrated markedly
mixed clinical outcomes, with some patients improving, oth-
ers remaining unchanged, and several progressing in severity
[19, 40–42]. Larger sample sizes are necessary for these MS
clinical trials, but the inconsistent results and lack of benefit
for most patients receiving autologous stem cell treatment
may be related to the biologic age of the transplanted cells.
Unfortunately, no MS clinical trial findings to date have been
reported separately for older participants (50 years). Thus,
MS clinical studies should focus on demonstrating the thera-
peutic potential, or lack thereof, of humanMSCs in patients of
various ages; such a study would be instrumental in determin-
ing the therapeutic effectiveness of older cells in MS patients
for the ultimate purpose of stem cell therapy optimization.
CONCLUSION
ASC transplantation is a novel therapy for MS patients who re-
spond poorly to standard treatment regimens. However, asMSC
clinical trials for MS patients become increasingly common, it
becomes crucial to understand the biologic changes and thera-
peutic effects of older donor stem cells, which will be adminis-
tered to older patients receiving autologous cell therapy.Numer-
ous studies have demonstrated the age-related molecular,
genetic, and in vitro changes ofMSCs, but the current study is the
first to demonstrate that MSCs derived from older donors are
less effective than their younger counterparts upon transplanta-
tion in the EAEmouse model of MS. Collectively, these data sup-
port the use of autologous MSC transplantation for young MS
patients only and highlight the need formore therapeutic testing
of autologous transplantation in older MS patients. Potential al-
logeneic cell therapy or modified autologous protocols for late-
onset MS patients may be necessary if older MSCs injected into
humans, as in EAEmice, fail to provide neuroprotection, amelio-
rate symptoms of neurodegeneration, or release known thera-
peutic agents upon stimulation.
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